YK Bioventures Opportunities Fund I, L.P. 4
4 · CERO THERAPEUTICS HOLDINGS, INC. · Filed Dec 10, 2024
Insider Transaction Report
Form 4
Transactions
- Sale
Common Stock
2024-12-06$0.12/sh−1,236,874$148,425→ 21,383,909 total(indirect: By YK Bioventures Opportunities Fund I, L.P.) - Sale
Common Stock
2024-12-10$0.09/sh−1,570,947$141,385→ 18,962,419 total(indirect: By YK Bioventures Opportunities Fund I, L.P.) - Sale
Common Stock
2024-12-09$0.11/sh−850,543$93,560→ 20,533,366 total(indirect: By YK Bioventures Opportunities Fund I, L.P.)
Footnotes (1)
- [F1]Securities are held directly by YK Bioventures Opportunities Fund I, L.P. (f/k/a YK Bioventures, LLC) ("YK Opps I"). YK Bioventures Opportunities GP I, LLC ("YK Opps I GP") is the general partner of YK Opps I and may be deemed to beneficially own the shares held by YK Opps I. Mitchell W. Kossar and Gary K. Yeung are managing partners of YK Opps I GP, and may be deemed to share voting and investment power over the shares held by YK Opps I. Each of YK Opps I GP and Messrs. Kossar and Yeung disclaims beneficial ownership of these shares except to the extent of its or his respective pecuniary interest therein.